Drugs and Biotech: Just Say "Maybe"

Analysts Herman Saftlas and Frank DiLorenzo see a spotty recovery -- but a few stocks, including Pfizer and Amgen, may be worth considering

The market rally has been healthy for stocks of drug and biotech companies, although progress in the latter arena has been spotty. That's the view of Herman Saftlas, Standard & Poor's senior investment officer covering pharmaceutical stocks, and S&P's Frank DiLorenzo, who tracks biotech.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.